

Simple and Efficient Amination of Diaryliodonium Salts with Aqueous Ammonia in Water without Metal-Catalyst

Jian Li ^{a,*}, Li Liu ^b

School of Pharmaceutical Engineering & Life Sciences, Chang Zhou University,

Analytical center, Chang Zhou University, Changzhou, 213164, P.R. China

E-mail: lijianchem@gmail.com

SUPPORTING INFORMATION

Contents

General Remarks	S 2
General Procedure for preparation of diaryliodonium salts	S 2
General procedure for amination	S 3
Characterization data for compounds 2	S 3
¹ H- and ¹³ C-NMR spectra for compounds 2	S 10
References	S 28


General Remarks.

All reactions were carried out under an air atmosphere condition. Various iodine reagents were purchased from Aldrich, Acros or Alfa. Flash column chromatography was performed using silica gel (200–300 mesh). Analytical thin-layer chromatography was performed using glass plates pre-coated with 200–300 mesh silica gel impregnated with a fluorescent indicator (254 nm). The model of GC-MS is Agilent 7890A(GC)-5975(MS). NMR spectra were recorded in CDCl_3 on a Bruker NMR-400 (400MHz) and Bruker NMR-500 (500MHz) with TMS as an internal reference. Products were characterized by comparison of ^1H NMR and ^{13}C NMR in the literatures.


General Procedure for preparation of diaryliodonium salts

All of diaryliodonium salts were prepared according references 1-3 in accordance with the following equations.

A. Preparation of Aryl (mesityl) iodonium trifluoromethane sulfonates^{1,3}




B. General procedure for diaryliodonium trifluoromethanesulfonates via tetrafluoroborates^{1,3}



General procedure for amination of Diaryliodonium Salts

Under nitrogen atmosphere, a solution of 25-28% aqueous ammonia (1mL) and Diaryliodonium Salts (0.40 mmol) was treated with NaOH (32 mg, 0.80 mmol) at 80°C for 2 hours. The temperature was allowed to cool slowly, the mixture was acidified with HCl (1M) and ethyl acetate (5 mL) were added, the organic layer was separated and concentrated, iodobenzene or iodomesitylene was obtained. Aqueous phase was alkalized by NaOH (1M) and extracted with ethyl acetate (5 mL), the organic layer was dried and concentrated to provide **2**. If necessary, the residues was purified by silica-gel column chromatography (Ethyl acetate / Petroleum ether = 1/4 - 1/2).


Characterization Data for Compounds **2**



2a

Aniline (**2a**)⁴


¹H NMR (400 MHz, CDCl₃) δ 7.15-7.11 (m, 2H), 6.74-6.71 (m, 1H), 6.66 (d, *J* = 7.6 Hz, 2H), 3.55 (brs, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 146.4, 129.2, 118.5, 115.1, 115.1, 115.0.



2b

4-Fluorobenzenamine (**2b**)⁴

¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, *J* = 16.0 Hz, 1H), 7.45 (d, *J* = 8.4 Hz, 1H), 7.35 (d, *J* = 8.40 Hz, 1H), 6.42 (d, *J* = 16.0 Hz, 1H), 3.80 (s, 3H); ¹³C NMR (100 MHz, CDCl₃,) δ 167.4, 143.5, 136.8, 136.2, 133.1, 132.9, 129.2, 118.4, 51.7.




2c

4-Chlorobenzenamine (2c)⁴

¹H NMR (400 MHz, CDCl₃) δ 7.10 (d, *J* = 8.0 Hz, 2H), 6.61 (d, *J* = 8.4 Hz, 2H), 3.63 (brs, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 145.0, 129.2, 123.2, 116.3.




2d

4-Bromobenzenamine (2d)⁴

¹H NMR (400 MHz, CDCl₃) δ 7.25 (m, 3H), 6.56 (d, *J* = 7.6 Hz, 2H), 3.64 (brs, 2H); ¹³C NMR

(125 MHz, CDCl₃) δ 154.4, 132.0, 116.7, 110.2.




2e

3-Bromobenzenamine (2e)⁵

¹H NMR (400 MHz, CDCl₃) δ 7.01-6.97 (m, 1H), 6.87-6.82 (m, 2H), 6.58 (d, *J* = 8.0 Hz, 1H),

3.68 (brs, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 141.1, 128.6, 128.0, 126.4, 126.2, 115.4.




2f

p-Toluidine (2f)⁴

¹H NMR (400 MHz, CDCl₃) δ 6.69 (d, *J* = 7.6 Hz, 2H), 6.60 (m, *J* = 7.6 Hz, 2H), 3.45 (brs, 2H),

2.23 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 143.8, 129.7, 139.7, 127.7, 115.2, 20.4.




2g

o-Toluidine (2g)⁶

^1H NMR (400 MHz, CDCl_3) δ 7.08 (d, $J = 7.6$ Hz, 2H), 6.77 (d, $J = 7.6$ Hz, 2H), 3.76 (brs, 2H);

^{13}C NMR (125 MHz, CDCl_3) δ 144.7, 130.6, 127.1, 122.4, 118.7, 115.0, 17.6.




2h

4-Methoxybenzenamine (2h)⁴

^1H NMR (400 MHz, CDCl_3) δ 6.75 (d, $J = 7.2$ Hz, 2H), 6.65 (d, $J = 8.0$ Hz, 2H), 3.74 (s, 3H),

3.18 (brs, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 152.8, 139.8, 116.4, 114.8, 55.7.




2i

3,4-Dimethoxybenzenamine (2i)⁷

^1H NMR (400 MHz, CDCl_3) δ 6.71 (d, $J = 8.0$ Hz, 1H), 6.31 (s, 1H), 6.24 (d, $J = 8.4$ Hz, 1H),

3.83 (d, $J = 11.6$ Hz, 6H); ^{13}C NMR (125 MHz, CDCl_3) δ 149.7, 142.3, 140.6, 113.3, 106.5, 100.9,


56.7, 55.7.



2j

2,4,6-Trimethylbenzenamine (2j)⁶


¹H NMR (400 MHz, CDCl₃) δ 6.75 (s, 2H), 3.42 (brs, 2H), 2.20 (s, 3H), 2.14 (s, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 140.1, 128.8, 127.1, 121.8, 20.3, 17.5.



2k

4-Nitrobenzenamine (2k)⁴


¹H NMR (400 MHz, CDCl₃) δ 8.08 (d, *J* = 8.0 Hz, 2H), 7.63 (d, *J* = 8.0 Hz, 2H), 4.37 (brs, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 152.4, 139.2, 126.3, 113.4.



2l

Biphenyl-4-amine (2l)⁴


¹H NMR (400 MHz, CDCl₃) δ 7.54 (d, *J* = 7.6 Hz, 2H), 7.42-7.36 (m, 4H), 7.30-7.25 (m, 1H), 6.76 (d, *J* = 7.2 Hz, 2H), 3.72 (brs, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 147.7, 130.7, 130.6, 123.8, 123.0, 121.3, 118.8, 117.8, 114.2, 113.6.



2m

Methyl 4-aminobenzoate (2m)⁵


¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, *J* = 7.6 Hz, 2H), 7.64 (d, *J* = 7.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 170.1, 155.5, 133.4, 119.3, 115.4, 52.4.



2n

Ethyl 4-aminobenzoate (2n)⁶


¹H NMR (400MHz, CDCl₃) δ 7.86 (d, *J* = 7.6 Hz, 2H), 6.64 (d, *J* = 7.2 Hz, 2H), 4.32 (q, *J* = 7.2 Hz, 2H), 4.04 (brs, 2H), 1.35 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 166.7, 150.7, 131.5, 120.1, 113.7, 60.3, 14.4.



2o

1-(4-Aminophenyl)ethanone (2o)⁴


¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, *J* = 7.6 Hz, 2H), 6.65 (d, *J* = 8.0 Hz, 2H), 4.10 (brs, 2H), 2.50 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) 151.1, 130.8, 127.9, 113.7, 26.0.



2p

4-Aminobenzonitrile (2p)⁶


¹H NMR (400 MHz, CDCl₃) δ 7.41 (d, *J* = 8.4 Hz, 2H), 6.65 (m, *J* = 8.0 Hz, 2H), 4.16 (brs, 3H).
¹³C NMR (125 MHz, CDCl₃) δ 150.4, 134.0, 133.8, 120.1, 114.5, 100.1.



2q

Naphthalen-1-amine (2q)⁶


^1H NMR (400 MHz, CDCl_3) δ 7.84-779 (m, 2H), 7.46-7.44 (m, 2H), 7.33-7.27 (m, 2H), 6.81-6.79 (m, 1H), 4.46 (brs, 2H); ^{13}C NMR(125 MHz, CDCl_3): δ 142.0, 134.4, 128.5, 126.3, 125.8, 124.8, 123.6, 120.7, 119.0.



2r

Pyridin-3-amine (2r)⁴


^1H NMR (400MHz, CDCl_3) δ 8.09 (s, 5H), 8.02 (d, J = 4.8 Hz, 1H), 7.08-7.04 (m, 1H), 6.97-6.95 (m, 1H), 3.69 (brs, 2H); ^{13}C NMR (125MHz, CDCl_3) δ 142.4, 140.0, 137.5, 123.7, 121.4.



2s

Pyridin-2-amine (2s)⁸


^1H NMR (400MHz, CDCl_3) δ 8.07 (s, 1H), 7.43 (t, J = 7.6 Hz, 1H), 6.63 (s, 1H), 6.50 (d, J = 8.4 Hz, 1H), 4.46 (brs, 2H); ^{13}C NMR (125MHz, CDCl_3) δ 158.4, 148.1, 137.7, 114.0, 108.6.



2t

6-methylpyridin-2-amine (2t)⁸


^1H NMR (400MHz, CDCl_3) δ 7.31 (t, J = 6.4 Hz, 1H), 6.51 (d, J = 7.2 Hz, 1H), 6.31 (d, J = 8.0 Hz, 1H), 4.43 (brs, 2H), 2.37(s, 3H); ^{13}C NMR (125MHz, CDCl_3) δ 157.8, 156.9, 138.0, 113.2, 105.3, 24.1.



2u

3-methylpyridin-2-amine (2u)⁸

¹H NMR (400MHz, CDCl₃) δ 7.94 (d, *J* = 4.8 Hz, 1H), 7.26 (d, *J* = 7.2 Hz, 1H), 6.62 (t, *J* = 6.4 Hz, 1H), 4.42 (brs, 2H), 2.12(s, 3H); ¹³C NMR (125MHz, CDCl₃) δ 157.1, 145.6, 145.6, 138.9, 138.7, 116.5, 114.4, 114.4, 17.1.




2v



thiophen-2-amine (2v)⁹


¹H NMR (400MHz, CDCl₃) δ 6.67 (s, 1H), 6.49 (d, *J* = 5.6 Hz, 1H), 6.18 (s, 1H), 4.68 (brs, 2H);
¹³C NMR (125MHz, CDCl₃) δ 151.1, 126.1, 112.6, 109.0.

^1H - and ^{13}C -NMR spectra for compounds 2






2a








2c








2d








2e










2f







2h












2k




liuli2/32 0508-4











2n








20








2p








2q










2r








2s










2u





2v



References

- 1) J. S. Harvey, S. P. Simonovich, C. R. Jamison and D. W. C. MacMillan, *J. Am. Chem. Soc.* 2011, **133**, 13782–13785.
- 2) M. Bielawski, M. Zhu and Olofssona, *B. Adv. Synth. Catal.* 2007, **349**, 2610–2618.
- 3) J. Li, L. Liu, Y.-Y. Zhou and S.-N. Xu, *RSC Advances*, 2012, **2**, 3207-3209.
- 4) Y. Li, X. - H. Zhu, F. Meng and Y. - Q. Wen, *Tetrahedron* 2011, **67**, 5450-5454.
- 5) L. Pehlivan, E. Metay, S. Laval, W. Dayoub, P. Demonchaux, G. Mignani and M. Lemaire, *Tetrahedron* 2011, **67**, 1971-1976.
- 6) D.-P. Wan, Q. Cai and K. Ding, *Adv. Synth. Catal.* 2009, **351**, 1722–1726.
- 7) X. Zeng, W.- M. Huang, Y.- T. Qiu and S. Jiang, *Org. Biomol. Chem.*, 2011, **9**, 8224-8227
- 8) M. K. Elmakdem, C. Fischmeister, C. M. Thomas, J.-L. Renaud, *Chem. Commun.*, 2010, **46**, 925-927.
- 9) R. Ntaganda , B. Dhudshia , C. L. B. Macdonald, A. N. Thadani *Chem. Commun.*, 2008, 6200-6202.